98%
921
2 minutes
20
Objectives: To investigate predictive factors of treatment response following ethanol sclerotherapy of large renal cysts via computed tomography (CT).
Methods: Retrospective study reviewed 71 patients (61.0 ± 13.2 years; M:F = 32:39) who underwent pretreatment CT and were treated with sclerotherapy of a large (> 5 cm) renal cyst (mean volume: 279.8 cc) using 99% ethanol from January 2010 to February 2019. Patients were followed up at least two times, short-term (defined as < 6 months, median 2.1 months) and long-term (defined as > 1 year, median 15.5 months), via ultrasound or CT. Suboptimal response was defined as the volume of residual cyst > 20 mL in each follow-up. Predictive variables of radiologic findings and radiomics features were analyzed using logistic regression analysis.
Results: Suboptimal response rates were 33.8% and 18.3% at short-term and long-term follow-ups, respectively. In radiologic findings, patients with suboptimal response in the short-term follow-up showed a more frequent estimated cyst volume ≥ 270 mL (OR 14.8, 95% CI 3.9-55.9, p < 0.001) and sinus protrusion (OR 7.0, 95% CI 1.7-28.5, p = 0.007). Cyst volume ≥ 270 mL was also associated with suboptimal response in the long-term follow-up (OR 4.6, 95% CI 1.3-16.9, p = 0.021). When radiomics features were combined, the area under the curve increased from 0.83 to 0.86 and from 0.68 to 0.82 to predict suboptimal response in short-term and long-term follow-ups, respectively.
Conclusion: Greater estimated volume, sinus protrusion, and radiomics features of the cysts in pretreatment CT can help predict suboptimal response of renal cyst after sclerotherapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00261-022-03621-2 | DOI Listing |
Diabetes Ther
September 2025
HaaPACS GmbH, Schriesheim, Germany.
Introduction: Weight and diabetes stigma among healthcare professionals (HCPs) may negatively impact treatment decisions, patient outcomes, and physician-patient interactions. We assessed the relationship between weight stigma, diabetes stigma, perceptions of healthcare quality, and avoidance of healthcare among adults with type 2 diabetes (T2D).
Methods: This observational, online survey-based study included 857 US adults with T2D.
Oncol Res
September 2025
Department of Biliary-Pancreatic Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Hepatocellular carcinoma (HCC) is a highly aggressive malignancy, largely driven by an immunosuppressive tumor microenvironment (TME) that facilitates tumor growth, immune escape, and resistance to therapy. Although immunotherapy-particularly immune checkpoint inhibitors (ICIs)-has transformed the therapeutic landscape by restoring T cell-mediated anti-tumor responses, their clinical benefit as monotherapy remains suboptimal. This limitation is primarily attributed to immunosuppressive components within the TME, including tumor-associated macrophages, regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs).
View Article and Find Full Text PDFFront Immunol
September 2025
Department of Clinical Oncology, University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Background: Neoantigen-based vaccines show promising therapeutic potential in solid tumors such as melanoma, GBM, NSCLC, and CRC. However, clinical responses remain suboptimal in stage IV patients, due to ineffective T-cell function and high tumor burdens. To overcome these limitations, our study investigates a combination strategy using neoantigen peptide vaccines and precision critical lesion radiotherapy (CLERT), which delivers immunomodulatory doses to key tumor regions synergistically enhance immune activation and inhibit progression in multifocal stage IV patients.
View Article and Find Full Text PDFAngew Chem Int Ed Engl
September 2025
Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, P.R. China.
The stimulator of interferon genes (STING) pathway is a central target in cancer immunotherapy, but current STING agonist therapies lack precision control, leading to suboptimal therapeutic outcomes and systematic adverse effects. Herein, we engineered a dual-locked immuno-polymeric nanoplatform (IPN) with precise spatiotemporal control over the release of STING agonists to enhance cancer immunotherapy. This platform, constructed from biocompatible poly(β-amino esters) (PBAE), incorporates the STING agonist (MSA-2) covalently linked via ester bonds, which is co-assembled with a sonosensitizer.
View Article and Find Full Text PDFAnal Chim Acta
November 2025
Institute of Materials Science, Vietnam Academy of Science and Technology, Hanoi, 10000, Viet Nam. Electronic address:
Background: Recent advancements in cancer therapeutics have catalyzed the development of noninvasive treatment modalities, including the utilization of fluorescent chemotherapeutic agents. These agents offer dual functionality, enabling targeted drug delivery, real-time tumor imaging, and personalized therapy monitoring. Such capabilities are instrumental in the progression toward more precise and effective cancer interventions.
View Article and Find Full Text PDF